Treatment of peripheral gangrene due to systemic sclerosis with intravenous pentoxifylline.
Vascular problems are very common in systemic sclerosis with 95% of patients suffering with Raynaud's phenomenon at some stage in their illness. Acute ischaemic lesions are much less common, but when they occur are a serious complication, and are often difficult to treat. Many drugs have been used in this situation, including both oral and intravenous vaso-dilators and low molecular weight dextran, each with varying degrees of success. The phospho-diesterase inhibitor, pentoxifylline, is reported to be useful in peripheral vascular disease, and in Raynaud's phenomenon, and the intravenous form is indicated for acute peripheral ischaemia, though its use in the context of connective tissue disease has not so far been reported. We now report the use of intravenous pentoxifylline in two patients with acute peripheral gangrene due to systemic sclerosis.
Goodfield
M J
MJ
Rowell
N R
NR
D000328:Adult; D000368:Aged; D005260:Female; D005385:Fingers / Q000473:pathology*; D005734:Gangrene / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D010431:Pentoxifylline / Q000008:administration & dosage* / Q000627:therapeutic use; D012595:Scleroderma, Systemic / Q000150:complications* / Q000473:pathology; D013805:Theobromine / Q000031:analogs & derivatives*
D013805:Theobromine; D010431:Pentoxifylline